Development Pipeline
 | Discovery | Preclinical | Phase 1 | Phase 2 | Phase 3 | |
| Discovery Preclinical Phase 1 Phase 2 Phase 3 | ||||||
| Compounds | ||||||
| ACH-3102NS5A Inhibitor | ||||||
| ACH-3422Nucleotide NS5B Polymerase Inhibitor | ||||||
| SovaprevirNS3/4A Protease Inhibitor | ||||||
| ACH-CFDIsComplement Factor D Inhibitors | ||||||
About Achillion
Headquartered in New Haven, CT,Achillion applies expertise in biology and structure-guided design and a deep understanding of patient and clinician needs to develop innovative treatment solutions aimed at improving the lives of patients. More...
HCV Education
About the Hepatitis C Virus
Hepatitis C is a worldwide epidemic affecting more than 150 million individuals. Click to learn more about this disease.
